IMPZY logo

Implanet S.A. (IMPZY) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Cotizando a $, Implanet S.A. (IMPZY) es una empresa del sector Healthcare valorada en 0. La acción obtiene una puntuación de 53/100, una calificación moderada basada en 9 KPI cuantitativos.

Ultimo analisis: 16 mar 2026
Puntuación de IA de 53/100

Implanet S.A. (IMPZY) Resumen de Asistencia Médica y Tuberías

Empleados46
Sede CentralMartillac, France

Implanet S.A. develops, manufactures, and sells orthopedic implants and surgical instruments, primarily focusing on spinal and knee solutions. Its Jazz platform for posterior fixation and Madison knee prostheses are distributed internationally. The company operates in a competitive medical device market, balancing innovation with regulatory and market access challenges.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 16 mar 2026

Tesis de Inversión

Implanet S.A. presents a speculative investment opportunity within the medical device sector. The company's focus on spinal and knee implants, particularly its Jazz platform, addresses a significant market need. However, with a market capitalization of $0.23 billion, negative profit margin of -43.4%, and a negative ROE of -450.0%, the company's financial performance raises concerns. Growth catalysts include potential expansion into new geographic markets and continued innovation in its product lines. Key value drivers will be the company's ability to improve its profitability, manage its operating expenses, and successfully commercialize new products. Investors should closely monitor the company's cash flow, sales growth, and competitive positioning.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • Market capitalization of $0.23 billion indicates a small-cap company with potential for high growth but also higher risk.
  • Negative profit margin of -43.4% reflects ongoing challenges in achieving profitability.
  • Gross margin of 44.0% suggests potential for profitability if operating expenses are managed effectively.
  • Negative ROE of -450.0% indicates significant challenges in generating returns for shareholders.
  • Beta of 0.70 suggests lower volatility compared to the overall market.

Competidores y Pares

Fortalezas

  • Specialized product portfolio in spinal and knee implants.
  • Established distribution network in key markets.
  • Proprietary technology in the Jazz platform.
  • Focus on innovation and product development.

Debilidades

  • Small market capitalization.
  • Negative profit margin and ROE.
  • Limited financial resources compared to larger competitors.
  • Reliance on a limited number of key products.

Catalizadores

  • Upcoming: Potential regulatory approvals for new products in key markets.
  • Upcoming: Announcement of strategic partnerships or acquisitions.
  • Ongoing: Continued expansion of the Jazz platform into new applications.
  • Ongoing: Increasing adoption of minimally invasive surgery techniques.
  • Ongoing: Growth in the global orthopedic device market.

Riesgos

  • Potential: Intense competition from larger medical device companies.
  • Potential: Stringent regulatory requirements and product liability risks.
  • Ongoing: Negative profit margin and ROE.
  • Ongoing: Limited financial resources compared to larger competitors.
  • Potential: Dependence on key personnel.

Oportunidades de crecimiento

  • Expansion into Emerging Markets: Implanet S.A. has the opportunity to expand its presence in emerging markets, such as Asia-Pacific and Latin America, where the demand for orthopedic implants is growing rapidly. These regions have a large and aging population, increasing rates of obesity and diabetes, and improving healthcare infrastructure. By establishing partnerships with local distributors and hospitals, Implanet can gain access to these markets and increase its sales. The global orthopedic device market is projected to reach $60 billion by 2028, offering substantial growth potential.
  • Product Innovation and Development: Implanet S.A. can drive growth by investing in research and development to create innovative products that address unmet clinical needs. This includes developing new spinal implants with improved biomechanical properties, as well as advanced knee prostheses with enhanced durability and functionality. By collaborating with surgeons and researchers, Implanet can identify emerging trends and develop products that meet the evolving needs of the market. The company's focus on innovation can differentiate it from competitors and attract new customers.
  • Strategic Partnerships and Acquisitions: Implanet S.A. can pursue strategic partnerships and acquisitions to expand its product portfolio, geographic reach, and technological capabilities. This includes partnering with other medical device companies to co-develop and co-market products, as well as acquiring companies with complementary technologies or market access. By leveraging the strengths of its partners and acquired companies, Implanet can accelerate its growth and create synergies that benefit all stakeholders. The medical device industry is characterized by consolidation, and strategic partnerships and acquisitions can be an effective way to gain a competitive advantage.
  • Focus on Minimally Invasive Surgery: Implanet S.A. can capitalize on the growing trend towards minimally invasive surgery (MIS) by developing implants and instruments that are specifically designed for MIS procedures. MIS techniques offer several advantages over traditional open surgery, including smaller incisions, less pain, faster recovery, and reduced risk of complications. By offering MIS-compatible products, Implanet can appeal to surgeons who are increasingly adopting these techniques. The market for MIS devices is growing rapidly, driven by patient demand and technological advancements.
  • Expansion of Knee Prostheses Line: Implanet S.A. can focus on expanding its knee prostheses line under the Madison name. The company can invest in research and development to create new knee implants with improved designs, materials, and functionalities. This includes developing customized knee implants that are tailored to the individual patient's anatomy, as well as advanced knee implants with enhanced durability and wear resistance. By offering a comprehensive range of knee prostheses, Implanet can attract a larger share of the knee replacement market.

Oportunidades

  • Expansion into emerging markets.
  • Development of new products and technologies.
  • Strategic partnerships and acquisitions.
  • Growing demand for minimally invasive surgery.

Amenazas

  • Intense competition from larger medical device companies.
  • Stringent regulatory requirements.
  • Pricing pressures from hospitals and payers.
  • Product liability risks.

Ventajas competitivas

  • Specialized product portfolio in spinal and knee implants.
  • Established distribution network in key markets.
  • Proprietary technology in the Jazz platform.

Acerca de IMPZY

Founded in 2006 and headquartered in Martillac, France, Implanet S.A. is a medical device company dedicated to improving outcomes in orthopedic surgery. The company develops, manufactures, and markets a range of implants and surgical instruments, focusing primarily on spinal and knee procedures. Implanet's flagship product is the Jazz platform, a comprehensive line of posterior fixation devices designed to address various spinal pathologies. The Jazz family includes Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, and Jazz Frame, along with the ISS-Jazz Screw systems. These products offer surgeons a versatile toolkit for spinal stabilization and correction. In addition to spinal implants, Implanet offers knee prostheses under the Madison name. These knee implants are designed to restore function and alleviate pain in patients with knee osteoarthritis. Implanet's products are sold directly and through distributors in France, the United States, Europe, the Middle East, Africa, and other international markets. The company also provides an ultrasonic osteotomy surgical system, further expanding its offerings in surgical solutions. Implanet operates in a competitive landscape, facing established players and emerging innovators in the orthopedic device market. The company's strategy focuses on innovation, clinical partnerships, and expanding its global reach to drive growth and improve patient care.

Qué hacen

  • Manufactures spinal implants for posterior fixation.
  • Develops knee prostheses for joint replacement.
  • Offers the Jazz platform, a comprehensive line of spinal fixation devices.
  • Provides ultrasonic osteotomy surgical systems.
  • Exports its products internationally.
  • Sells products directly and through distributors.

Modelo de Negocio

  • Develops and manufactures orthopedic implants and surgical instruments.
  • Sells products to hospitals and surgeons through direct sales and distributors.
  • Generates revenue from the sale of spinal and knee implants.

Contexto de la Industria

Implanet S.A. operates within the global medical device industry, which is characterized by continuous innovation, stringent regulatory requirements, and intense competition. The orthopedic segment, specifically spinal and knee implants, is driven by an aging population, increasing prevalence of musculoskeletal disorders, and advancements in surgical techniques. The market is dominated by large multinational corporations, but smaller companies like Implanet can compete by focusing on niche markets and innovative technologies. The industry is subject to regulatory oversight by agencies such as the FDA in the United States and the EMA in Europe.

Clientes Clave

  • Hospitals
  • Orthopedic surgeons
  • Distributors of medical devices
Confianza de la IA: 71% Actualizado: 16 mar 2026

Finanzas

Gráfico e información

Precio de la acción de Implanet S.A. (IMPZY): Price data unavailable

Últimas noticias

No hay noticias recientes disponibles para IMPZY.

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para IMPZY.

Objetivos de Precios

Análisis del precio objetivo de Wall Street para IMPZY.

MoonshotScore

53/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de IMPZY en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Información de ADR de Implanet S.A. No patrocinado

Implanet S.A. (IMPZY) cotiza en los EE. UU. como un recibo de depósito estadounidense (ADR).

  • Nivel de ADR: 1
  • Ratio de ADR: 1:1
  • Ticker del mercado local: IMPZ

Información del mercado OTC de IMPZY

The OTC Other tier represents the lowest tier of the OTC market, indicating that Implanet S.A. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and prospects. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ.

  • Nivel OTC: OTC Other
  • Estado de divulgación: Unknown
Liquidez: Liquidity for IMPZY is likely very limited given its OTC Other listing. Expect wide bid-ask spreads and difficulty executing large trades without significantly impacting the price. Investors should exercise extreme caution due to potential price volatility and the risk of being unable to exit their positions quickly.
Factores de riesgo OTC:
  • Limited financial disclosure.
  • Low trading volume and liquidity.
  • Potential for price manipulation.
  • Higher risk of fraud or mismanagement.
  • Limited regulatory oversight.
Lista de verificación de diligencia debida:
  • Verify the company's legal status and registration.
  • Attempt to locate and review any available financial statements.
  • Research the background and experience of the company's management team.
  • Assess the company's business model and competitive landscape.
  • Understand the risks associated with investing in OTC Other stocks.
  • Consult with a qualified financial advisor.
  • Confirm share structure and any potential dilution.
Señales de legitimidad:
  • Company has been in operation since 2006.
  • Company has international sales and distribution.
  • Company has a portfolio of medical devices with regulatory approvals.

Acciones de Implanet S.A.: Preguntas Clave Respondidas

¿Cuáles son los factores clave para evaluar IMPZY?

Implanet S.A. (IMPZY) actualmente tiene una puntuación IA de 53/100, indicando puntuación moderada. Fortaleza clave: Specialized product portfolio in spinal and knee implants.. Riesgo principal a monitorear: Potential: Intense competition from larger medical device companies.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de IMPZY?

IMPZY actualmente puntúa 53/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de IMPZY?

Los precios de IMPZY se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre IMPZY?

La cobertura de analistas para IMPZY incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en IMPZY?

Las categorías de riesgo para IMPZY incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Intense competition from larger medical device companies.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de IMPZY?

La relación P/E para IMPZY compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.

¿Está IMPZY sobrevalorada o infravalorada?

Determinar si Implanet S.A. (IMPZY) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de IMPZY?

Implanet S.A. (IMPZY) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • Information is based on available company data and may be limited due to the company's OTC listing.
Fuentes de datos

Popular Stocks